Cancer biomarker HER-2/neu in breast cancer in Indian women

Rajeev Singhai1, Amit V Patil2, Vinayak W Patil11Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India; 2Department of General Surgery, Government Medical College, Miraj, Maharashtra, IndiaAim and objectives: In Indian women with breast cancer, the HER-2/neu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Singhai R, Patil VW, Patil AV
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a17f1623757842ac95bcb9d9af75bb38
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a17f1623757842ac95bcb9d9af75bb38
record_format	dspace
spelling	oai:doaj.org-article:a17f1623757842ac95bcb9d9af75bb382021-12-02T07:42:10ZCancer biomarker HER-2/neu in breast cancer in Indian women1179-1314https://doaj.org/article/a17f1623757842ac95bcb9d9af75bb382011-03-01T00:00:00Zhttp://www.dovepress.com/cancer-biomarker-her-2neu-in-breast-cancer-in-indian-women-a6877https://doaj.org/toc/1179-1314Rajeev Singhai1, Amit V Patil2, Vinayak W Patil11Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India; 2Department of General Surgery, Government Medical College, Miraj, Maharashtra, IndiaAim and objectives: In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors.Materials and methods: Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients&#39; age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels.Results: Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity.Conclusion: HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available.Keywords: breast cancer, serum HER-2/neu receptor assay, hormone receptor, ER, PgR Singhai RPatil VWPatil AVDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2011, Iss default, Pp 21-26 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Singhai R Patil VW Patil AV Cancer biomarker HER-2/neu in breast cancer in Indian women
description	Rajeev Singhai1, Amit V Patil2, Vinayak W Patil11Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India; 2Department of General Surgery, Government Medical College, Miraj, Maharashtra, IndiaAim and objectives: In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors.Materials and methods: Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients&#39; age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels.Results: Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity.Conclusion: HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available.Keywords: breast cancer, serum HER-2/neu receptor assay, hormone receptor, ER, PgR
format	article
author	Singhai R Patil VW Patil AV
author_facet	Singhai R Patil VW Patil AV
author_sort	Singhai R
title	Cancer biomarker HER-2/neu in breast cancer in Indian women
title_short	Cancer biomarker HER-2/neu in breast cancer in Indian women
title_full	Cancer biomarker HER-2/neu in breast cancer in Indian women
title_fullStr	Cancer biomarker HER-2/neu in breast cancer in Indian women
title_full_unstemmed	Cancer biomarker HER-2/neu in breast cancer in Indian women
title_sort	cancer biomarker her-2/neu in breast cancer in indian women
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/a17f1623757842ac95bcb9d9af75bb38
work_keys_str_mv	AT singhair cancerbiomarkerher2neuinbreastcancerinindianwomen AT patilvw cancerbiomarkerher2neuinbreastcancerinindianwomen AT patilav cancerbiomarkerher2neuinbreastcancerinindianwomen
_version_	1718399240250589184

Cancer biomarker HER-2/neu in breast cancer in Indian women

Ejemplares similares